source
- Pharma pours billions into bispecifics, ADCs and cell therapies despite limited clinical proofThe article notes that emerging drug formats such as bispecific antibodies, antibody‑drug conjugates and cell therapies have yet to demonstrate clear clinical success, yet pharmaceutical firms cont…
- FDA issues final guidance on developing and labeling prescription drug appsThe FDA released its final guidance on Tuesday, outlining how drug sponsors should create, distribute, and label software applications that are used together with prescription medicines. The guida…